Unknown

Dataset Information

0

Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations.


ABSTRACT: Tyrosinemia type I (hepatorenal tyrosinemia, HT-1) is an autosomal recessive condition resulting in hepatic failure with comorbidities involving the renal and neurologic systems and long term risks for hepatocellular carcinoma. An effective medical treatment with 2-[2-nitro-4-trifluoromethylbenzoyl]-1,3-cyclohexanedione (NTBC) exists but requires early identification of affected children for optimal long-term results. Newborn screening (NBS) utilizing blood succinylacetone as the NBS marker is superior to observing tyrosine levels as a way of identifying neonates with HT-1. If identified early and treated appropriately, the majority of affected infants can remain asymptomatic. A clinical management scheme is needed for infants with HT-1 identified by NBS or clinical symptoms. To this end, a group of 11 clinical practitioners, including eight biochemical genetics physicians, two metabolic dietitian nutritionists, and a clinical psychologist, from the United States and Canada, with experience in providing care for patients with HT-1, initiated an evidence- and consensus-based process to establish uniform recommendations for identification and treatment of HT-1. Recommendations were developed from a literature review, practitioner management survey, and nominal group process involving two face-to-face meetings. There was strong consensus in favor of NBS for HT-1, using blood succinylacetone as a marker, followed by diagnostic confirmation and early treatment with NTBC and diet. Consensus recommendations for both immediate and long-term clinical follow-up of positive diagnoses via both newborn screening and clinical symptomatic presentation are provided.

SUBMITTER: Chinsky JM 

PROVIDER: S-EPMC5729346 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations.

Chinsky Jeffrey M JM   Singh Rani R   Ficicioglu Can C   van Karnebeek Clara D M CDM   Grompe Markus M   Mitchell Grant G   Waisbren Susan E SE   Gucsavas-Calikoglu Muge M   Wasserstein Melissa P MP   Coakley Katie K   Scott C Ronald CR  

Genetics in medicine : official journal of the American College of Medical Genetics 20170803 12


Tyrosinemia type I (hepatorenal tyrosinemia, HT-1) is an autosomal recessive condition resulting in hepatic failure with comorbidities involving the renal and neurologic systems and long term risks for hepatocellular carcinoma. An effective medical treatment with 2-[2-nitro-4-trifluoromethylbenzoyl]-1,3-cyclohexanedione (NTBC) exists but requires early identification of affected children for optimal long-term results. Newborn screening (NBS) utilizing blood succinylacetone as the NBS marker is s  ...[more]

Similar Datasets

| S-EPMC8620914 | biostudies-literature
| S-EPMC5203850 | biostudies-literature
| S-EPMC6852597 | biostudies-literature
| S-EPMC8173906 | biostudies-literature
| S-EPMC4608291 | biostudies-other
| S-EPMC9068356 | biostudies-literature
| S-EPMC6921946 | biostudies-literature
| S-EPMC8628757 | biostudies-literature
| S-EPMC7568425 | biostudies-literature
| S-EPMC9021334 | biostudies-literature